184 related articles for article (PubMed ID: 34143937)
1. The nonsmokers' and smokers' pathways in lung adenocarcinoma: Histological progression and molecular bases.
Okudela K; Matsumura M; Arai H; Woo T
Cancer Sci; 2021 Sep; 112(9):3411-3418. PubMed ID: 34143937
[TBL] [Abstract][Full Text] [Related]
2. Specific expression of MUC21 in micropapillary elements of lung adenocarcinomas - Implications for the progression of EGFR-mutated lung adenocarcinomas.
Matsumura M; Okudela K; Nakashima Y; Mitsui H; Denda-Nagai K; Suzuki T; Arai H; Umeda S; Tateishi Y; Koike C; Kataoka T; Irimura T; Ohashi K
PLoS One; 2019; 14(4):e0215237. PubMed ID: 30973916
[TBL] [Abstract][Full Text] [Related]
3. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
4. Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma.
Koike C; Okudela K; Matsumura M; Mitsui H; Suzuki T; Arai H; Kataoka T; Ishikawa Y; Umeda S; Tateishi Y; Ohashi K
Histol Histopathol; 2021 Mar; 36(3):305-315. PubMed ID: 33368138
[TBL] [Abstract][Full Text] [Related]
5. A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential - An Implication of Micropapillary Element.
Matsumura M; Okudela K; Kojima Y; Umeda S; Tateishi Y; Sekine A; Arai H; Woo T; Tajiri M; Ohashi K
PLoS One; 2016; 11(11):e0166795. PubMed ID: 27861549
[TBL] [Abstract][Full Text] [Related]
6. Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status.
Sousa V; Rodrigues C; Silva M; Alarcão AM; Carvalho L
Rev Port Pneumol (2006); 2015; 21(3):113-25. PubMed ID: 25926253
[TBL] [Abstract][Full Text] [Related]
7. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
Ruiz-Cordero R; Ma J; Khanna A; Lyons G; Rinsurongkawong W; Bassett R; Guo M; Routbort MJ; Zhang J; Skoulidis F; Heymach J; Roarty EB; Tang Z; Medeiros LJ; Patel KP; Luthra R; Roy-Chowdhuri S
BMC Cancer; 2020 Jan; 20(1):83. PubMed ID: 32005111
[TBL] [Abstract][Full Text] [Related]
8. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
Colombino M; Paliogiannis P; Cossu A; Santeufemia DA; ; Sini MC; Casula M; Palomba G; Manca A; Pisano M; Doneddu V; Palmieri G
BMC Pulm Med; 2019 Nov; 19(1):209. PubMed ID: 31711449
[TBL] [Abstract][Full Text] [Related]
9. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
[TBL] [Abstract][Full Text] [Related]
10. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
[TBL] [Abstract][Full Text] [Related]
11. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
12. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
Singh V; Guleria P; Malik PS; Mohan A; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Jain D
Curr Probl Cancer; 2019 Oct; 43(5):391-401. PubMed ID: 30591192
[TBL] [Abstract][Full Text] [Related]
14. A subpopulation of airway epithelial cells that express hepatocyte nuclear factor 4α - its implication in the development of non-terminal respiratory unit-type lung adenocarcinoma.
Okudela K; Arai H; Kitamura H; Baba T; Mitsui H; Suzuki T; Sugiyama M; Honda E; Matsumura M; Takemura T; Kataoka T; Koike C; Tateshi Y; Tajiri M; Ogura T; Ohashi K
Histol Histopathol; 2019 Nov; 34(11):1217-1227. PubMed ID: 30848476
[TBL] [Abstract][Full Text] [Related]
15. Reciprocal expression of trefoil factor-1 and thyroid transcription factor-1 in lung adenocarcinomas.
Matsubara D; Yoshimoto T; Soda M; Amano Y; Kihara A; Funaki T; Ito T; Sakuma Y; Shibano T; Endo S; Hagiwara K; Ishikawa S; Fukayama M; Murakami Y; Mano H; Niki T
Cancer Sci; 2020 Jun; 111(6):2183-2195. PubMed ID: 32237253
[TBL] [Abstract][Full Text] [Related]
16. Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma.
Lee JJ; Park S; Park H; Kim S; Lee J; Lee J; Youk J; Yi K; An Y; Park IK; Kang CH; Chung DH; Kim TM; Jeon YK; Hong D; Park PJ; Ju YS; Kim YT
Cell; 2019 Jun; 177(7):1842-1857.e21. PubMed ID: 31155235
[TBL] [Abstract][Full Text] [Related]
17. MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis.
Dong Y; Zhou L; Zhao D; Li K; Liu Z; Che N; Liu H
Jpn J Clin Oncol; 2020 Jun; 50(6):701-711. PubMed ID: 32083303
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.
Rodriguez EF; VandenBussche CJ; Chowsilpa S; Maleki Z
Cancer Cytopathol; 2018 Oct; 126(10):853-859. PubMed ID: 30199148
[TBL] [Abstract][Full Text] [Related]
20. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
